Source-grounded facts extracted from Damora Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Damora Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.
“4. Ratification of Auditor Proposal . For Against Abstain Broker Non-Votes 54,977,317 5,640 26,981 -”
Damora Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes to approve executive compensation at the 2026-06-17 meeting.
“3. Say-on-Frequency Proposal . 1 Year 2 Years 3 Years Abstain 50,913,167 103 518,015 1,267”
Damora Therapeutics, Inc. shareholders approved Advisory vote to approve the compensation paid to the named executive officers at the 2026-06-17 meeting.
“2. Say-on-Pay Proposal . For Against Abstain Broker Non-Votes 51,401,988 3,546 27,018 3,577,386”
Damora Therapeutics, Inc. shareholders approved Election of Michael Landsittel and Cameron Turtle, D.Phil as Class III directors at the 2026-06-17 meeting.
“1. Election of Directors Proposal . Nominees For Withheld Broker Non-Votes Michael Landsittel 51,403,541 29,011 3,577,386 Cameron Turtle, D.Phil 51,403,540 29,012 3,577,386”
Brian Burkavage was appointed as principal financial officer and principal accounting officer at Damora Therapeutics, Inc..
“the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.”
Lori Firmani departed as Chief Financial Officer at Damora Therapeutics, Inc..
“the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.”
Damora Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.
“On April 17, 2026, the Audit Committee engaged Ernst & Young LLP (“EY US”) as the Company’s independent registered public accounting firm, effective immediately.”
Damora Therapeutics, Inc. dismissed EY Godkendt Revisionspartnerselskab as its auditor.
“On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s independent registered public accounting firm, effective immediately.”
Damora Therapeutics, Inc.: Amended certificate of incorporation to change company name from Galecto, Inc. to Damora Therapeutics, Inc (effective 2026-03-10).
“On March 6, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from "Galecto, Inc." to "Damora Therapeutics, Inc." (the "Name Change Amendment"). The Name Change Amendment became effective at 12:01 a.m. Eastern Time on March 10, 2026.”
Damora Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein valued at approximately $295.9 million (effective 2026-02-10).
“On February 10, 2026, Galecto, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,473,685 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a public offering price of $19.00 per share.”
Damora Therapeutics, Inc.: Certificate of Amendment to increase authorized shares of common stock from 300,000,000 to 500,000,000, effective upon filing on February 9, 2026 (effective 2026-02-09).
“On February 9, 2026, in connection with the approval by stockholders of the Company at a special meeting of stockholders (the “Special Meeting”) as described in Item 5.07 below, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, par value $0.00001 per share (“Common Stock”), from 300,000,000 to 500,000,000, which became effective upon filing.”
Damora Therapeutics, Inc. issued up to 628,302 shares of warrant to Paramora Holding LLC.
“we issued to Paramora a warrant to purchase an aggregate of up to 628,302 shares of our common stock, with a per share exercise price equal to $23.01, which was the closing price of a share of the Company's common stock on December 31, 2025”
Damora Therapeutics, Inc.: Corrected authorized shares of Series C Preferred Stock from 43,855 to 43,882 (effective 2025-12-05).
“On December 5, 2025, the Company filed with the Delaware Secretary of State a Certificate of Correction (the “Certificate of Correction”) to the Certificate of Designation of Series C Preferred Stock to correct an inadvertent error in the number of shares of Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the “Series C Preferred Stock”), that the Company is authorized to issue by modifying Section 2 of the Certificate of Designation of Series C Preferred Stock to correctly state that the number of authorized shares of Series C Preferred Stock is 43,882 shares instead of 43,855 shares.”
Damora Therapeutics, Inc.: Filed Certificates of Designation for Series B and Series C Preferred Stock, creating new stock series with specific rights and limitations (effective 2025-11-07).
“On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.”
Damora Therapeutics, Inc. completed an acquisition involving Damora Therapeutics, Inc. (closed 2025-11-10).
“On November 10, 2025, the Company completed its business combination with Damora.”
Amy Wechsler was appointed as Director at Damora Therapeutics, Inc..
“appointed Amy Wechsler to join the Board, effective as of October 11, 2024.”
Damora Therapeutics, Inc. completed an acquisition involving Bridge Medicines LLC for 62,594 shares of common stock and 160.562 shares of Series A non-voting convertible preferred stock (closed 2024-10-07).
“Agreement, at the closing of the Asset Purchase (the “ Closing ”), as consideration to Bridge Medicines for the Asset Purchase, the Company (a) issued to Bridge Medicines (i) 62,594 shares (the “ Common Stock Payment Shares ”) of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), and (ii) 160.562 shares (the “ Preferred Stock”
Damora Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“September 27, 2023, Galecto, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, a”
Damora Therapeutics, Inc. announced a restructuring with charges of approximately $2.8 million in restructuring charges affecting workforce reduction (29 people, or approximately 70% of the Company’s existing headcount).
“of the Company’s existing headcount. The Restructuring Plan was communicated to employees starting on September 20, 2023. The Company estimates that it will incur approximately $2.8 million in restructuring charges in connection with the restructuring, consisting of (i) approximately $2.6 million in cash-based expenses related to employee severance and notice period”
Bertil Lindmark departed as Chief Medical Officer at Damora Therapeutics, Inc..
“on September 21, 2023, the Company informed Bertil Lindmark, M.D., the Company’s Chief Medical Officer, that his position will be eliminated and that his duties will be assumed by Hans Schambye, M.D., Ph.D., the Company’s Chief Executive Officer.”
Damora Therapeutics, Inc. shareholders approved Ratification of the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“(b) Ratification of the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the voting included 16,042,725 votes for, 52,661 votes against and 26,976 votes abstained. There were no broker non-votes regarding this proposal.”
Damora Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-06-14 meeting.
“(a) Election of Class III Directors. Director Nominee Votes For Votes Withheld Jayson Dallas, M.D. 9,917,146 696,399 Amit Munshi 10,526,701 86,844 Hans Schambye, M.D., Ph.D. 10,508,799 104,746 There were 5,508,817 broker non-votes regarding the election of directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.